文献速递炎症性肠病胃肠动力与功能性疾病

接纳承诺疗法用于伴心理困扰的炎症性肠病成人:一项随机对照试验

Acceptance and Commitment Therapy for Adults Living With Inflammatory Bowel Disease and Distress: A Randomized Controlled Trial.
PubMed 文献 · Am J Gastroenterol · 2024-08-20

该随机对照试验将120例伴心理困扰的炎症性肠病成人分为接纳承诺疗法(ACT)组61例与认知行为疗法式心理教育主动对照组59例,两种方案均以线上混合形式实施。ACT组在健康相关生活质量及克罗恩病活动度方面较对照组显著改善,作者认为ACT可作为炎症性肠病整合照护中的辅助治疗。

要点

  • ACT组健康相关生活质量较主动对照组显著改善,效应量中等(β=0.41)。
  • ACT组克罗恩病活动度较主动对照组显著降低,效应量大(β=-0.77)。
  • 两种方案均使多数结局随时间改善,但组间差异不显著。

核心结论

  • 两种方案均对伴心理困扰的炎症性肠病患者有益,但ACT在健康相关生活质量和自报克罗恩病活动度方面提供显著额外获益,作者认为其可能是炎症性肠病整合照护中有用的辅助治疗。

研究设计与样本

  • 随机对照试验,共纳入120例伴心理困扰的炎症性肠病成人,随机分为ACT干预组61例与认知行为疗法式心理教育主动对照组59例。
  • 两种方案均通过线上混合形式实施,即治疗师主导与参与者主导相结合的形式。
  • 采用线性混合模型评估基线、干预后及3个月随访时研究结局变化率的组间差异。

主要发现

  • 主要结局健康相关生活质量在ACT组较主动对照组显著改善,基线至干预后变化率差异有统计学意义(t[190]=2.15,P=0.033),效应量中等(β=0.41,均数差=0.07,95%CI 0.01-0.12,P=0.014)。
  • 次要结局克罗恩病活动度在ACT组较主动对照组显著降低,基线至3个月随访变化率差异有统计学意义(t[90]=-2.40,P=0.018),效应量大(β=-0.77,均数差=-9.43,95%CI -13.72至-5.13,P<0.001)(P=0.014)。
  • 分别观察各组结局随时间变化率时,焦虑症状和疼痛仅在ACT组显著改善,而溃疡性结肠炎活动度和应激症状仅在主动对照组显著改善。
  • 其余14项结局在两组均随时间显著改善,包括炎症性肠病活动度、胃肠道无益思维模式、内脏焦虑、疲劳干扰、疲劳严重度、疲劳频率、心理 inflexibility、自我效能、心理韧性、当前健康状况、抑郁症状、炎症性肠病控制感及疼痛灾难化,但这些变化组间差异不显著。

关键数值与推荐

  • 主要结局健康相关生活质量:ACT组较主动对照组改善,均数差=0.07(95%CI 0.01-0.12,P=0.014),β=0.41。
  • 克罗恩病活动度:ACT组较主动对照组降低,均数差=-9.43(95%CI -13.72至-5.13,P<0.001),β=-0.77。

临床怎么用

  • 作者认为ACT可能是有用的辅助治疗,可纳入炎症性肠病整合照护。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The bidirectional relationship between disease activity and mental health in inflammatory bowel disease (IBD) has prompted investigations into the efficacy of psychotherapeutic interventions such as acceptance and commitment therapy (ACT) on biopsychosocial outcomes. We aimed to examine the efficacy of an ACT program (intervention) in comparison with a cognitive behavioral therapy-informed psychoeducation program (active control) for individuals with IBD and coexistent psychological distress. Both programs were delivered online through a hybrid format (i.e., therapist-led and participant-led sessions). METHODS: A total of 120 adults with IBD were randomized to either the intervention (N = 61) or active control groups (N = 59). Efficacy was determined using linear mixed models for group differences, in rate of changes in study outcomes, between baseline, postintervention, and 3-month follow-up. RESULTS: The primary outcome health-related quality of life significantly improved in the intervention group when compared with the active control group, with a significantly different rate of change observed from baseline to postintervention ( t [190] = 2.15, P = 0.033) in favor of the intervention group with a medium effect size (β = 0.41, mean difference = 0.07, 95% confidence interval 0.01-0.12, P = 0.014). Similarly, the secondary outcome Crohn's disease activity significantly reduced in the intervention group when compared with the active control group, with a significantly different rate of change observed from baseline to 3-month follow-up ( t [90] = -2.40, P = 0.018) in favor of the intervention group with a large effect size (β = -0.77, mean difference = -9.43, 95% confidence interval -13.72 to -5.13, P < 0.001) ( P = 0.014). Furthermore, when observing the rate of change in outcomes over time for the groups separately, anxiety symptoms and pain significantly improved in the intervention group only, and conversely, ulcerative colitis activity and stress symptoms significantly improved in the active control group only. All other outcomes (N = 14) significantly improved over time in both groups including IBD activity, gastrointestinal unhelpful thinking patterns, visceral anxiety, fatigue interference, fatigue severity, fatigue frequency, psychological inflexibility, self-efficacy, resilience, current health status, depression symptoms, IBD control, and pain catastrophizing; however, these changes were not significantly different between the groups. DISCUSSION: Both programs were of benefit to people with IBD and distress. However, ACT offers a significant added benefit for health-related quality of life and self-reported Crohn's disease activity and may be a useful adjuvant therapy in integrated IBD care.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Naude C, Skvarc D, Maunick B, et al. Acceptance and Commitment Therapy for Adults Living With Inflammatory Bowel Disease and Distress: A Randomized Controlled Trial. Am J Gastroenterol. 2024. PMID: 39162706. doi:10.14309/ajg.0000000000003032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。